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Abstract
Background: Chemotherapy can prompt the evolution of classical drug resistance, but selection
can also favour other parasite traits that confer a survival advantage in the presence of drugs. The
experiments reported here test the hypothesis that sub-optimal drug treatment of malaria
parasites might generate survival and transmission advantages for virulent parasites.
Methods: Two Plasmodium chabaudi lines, one derived from the other by serial passage, were used
to establish avirulent and virulent infections in mice. After five days, infections were treated with
various doses of pyrimethamine administered over 1 or 4 days. Virulence measures (weight and
anaemia), parasite and gametocyte dynamics were followed until day 21.
Results: All treatment regimes reduced parasite and gametocyte densities, but infections with the
virulent line always produced more parasites and more gametocytes than infections with the
avirulent line. Consistent with our hypothesis, drug treatment was disproportionately effective
against the less virulent parasites. Treatment did not affect the relative transmission advantage of
the virulent line. Neither of the lines contained known mutations conferring classical drug
resistance.
Conclusion:  Drug-sensitivity of malaria parasites can be virulence-dependent, with virulent
parasites more likely to survive sub-optimal treatment. If this proves to be general for a variety of
drugs and parasite species, selection imposed by sub-optimal drug treatment could result in the
evolution of more aggressive malaria parasites.
Background
Patients in endemic areas often carry malaria parasites
while having levels of antimalarial drugs in their blood
that fail to eliminate all parasites. This can be due to the
presence of residual levels of drugs when a new infection
is acquired [1,2], because recommended treatment could
not clear all parasites [3-6] or because of inadequate treat-
ment (for example from low quality drugs [7,8] or poor
compliance). Due to variable metabolic drug uptake
[9,10], recommended doses may not be adequate for all
sub-groups, such as children or pregnant women
[4,11,12]. Even during supervised treatment with potent
and high quality drugs, including artemisinin-based com-
bination therapies, patients can be cured from disease
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symptoms but low numbers of parasites to survive and
transmit [5,13,14]. In all these cases, drugs are not main-
tained at sufficient doses for long enough to kill all para-
sites.
Exposure of parasites to sub-optimal drug levels can facil-
itate the evolution of classical drug resistance, where
resistant parasites survive drug treatment through well-
studied mechanisms, such as target-site mutations and
detoxification or efflux pathways [15]. In what follows,
such mechanisms are referred to as 'classical drug resist-
ance'. However, genetically-encoded parasite traits other
than classical resistance could also influence survival in
drug-treated infections [16-20] and, hence, be subject to
drug-induced selection pressures. For instance, malaria
parasites vary in virulence (the harm caused to hosts as a
consequence of infection) [21-23], the molecular basis of
which is beginning to be understood [24-26]. Here it is
proposed that virulence affects drug sensitivity. For
instance, in some cases, parasite lines which replicated
rapidly or which can persist at higher densities for longer
are associated with more severe disease (virulence)
[21,27,28]. This could make them less vulnerable to drug
treatment if they can rapidly recover high parasite densi-
ties after a bout of drug-induced mortality. Alternatively,
rapid replication could render parasites more vulnerable
to metabolic disruption and thus, greater drug-induced
mortality. In either case, the evolution of higher or lower
virulence could be a consequence of drug-induced selec-
tion. Testing whether a given drug regime has differential
effects on virulent and avirulent parasites is the first key
step in testing the hypothesis that chemotherapy has the
potential to impose selection for parasite traits other than
those involved in classical resistance (Figure 1). Such
selection processes may be occurring in the field but are
difficult to study due to various confounding factors,
including the presence of multiple, interbreeding parasite
genotypes. Therefore, in vivo experiments using an animal
model were designed to test if sensitivity to drug treatment
can be virulence-dependent.
Methods
Terminology
Drug resistance
The WHO defines drug resistance as "the ability of a para-
site strain to survive or multiply in the presence of drug
concentrations that normally destroy parasites of the
same species or prevent their multiplication, provided
that the drug was properly absorbed and parasites
exposed to it" [29]. This definition includes all parasite
traits that affect the survival or transmission of parasites
exposed to drugs. Drug resistance in malaria is acquired
through selection of mutants that are favoured under con-
ditions of drug exposure. This includes mutations directly
related to the action of the drug ('classical drug resist-
ance'), but also other parasite traits that, directly or indi-
rectly, may confer a survival and transmission advantage
in the presence of drugs (non-classical drug resistance). As
was hypothesised above, parasite replication rate could be
an example of such a non-classical resistance trait,
whereas target site mutations, and efflux and detoxifica-
Possible outcomes for the relation between drug sensitivity and virulence Figure 1
Possible outcomes for the relation between drug sensitivity and virulence. Without drug treatment (black symbols), 
infections with the virulent parasite line (Vir) produce more parasites compared to the avirulent line (Avir). If both lines are 
affected similarly by drug treatment (open symbols), the proportionate difference between them will be unaffected by drug 
treatment (1A). If the virulent line is less sensitive to drug treatment, the reduction in parasite numbers will be disproportion-
ately greater for the avirulent line (1B). If the virulent line is more sensitive to drug treatment, the reduction in parasite num-
bers will be disproportionately greater for the virulent line (1C).
Avir Vir
p
a
r
a
s
i
t
e
s
Avir Vir
p
a
r
a
s
i
t
e
s
Avir Vir
L
o
g
 
n
u
m
b
e
r
 
p
a
r
a
s
i
t
e
s
AC BMalaria Journal 2008, 7:257 http://www.malariajournal.com/content/7/1/257
Page 3 of 11
(page number not for citation purposes)
tion mechanisms are examples of classical resistance.
Non-classical drug resistance is the subject of this study.
Sub-curative vs. sub-optimal
Ideally, drug treatment achieves two things: restoration of
patient health and clearance of parasites. In the literature,
the term 'cure' is used variably to refer to either or both of
these outcomes. Therefore, the term 'sub-curative drug-
treatment' is ambiguous. For clarity, the term 'sub-opti-
mal drug-treatment' is used here and specifically defined
as drug treatment that allows classically drug-sensitive
parasites to survive, with or without eliminating disease
symptoms.
Experimental overview and rationale
Here, the first experimental tests of how genetically
related parasites, differing in virulence, perform under a
range of drug treatment regimes are presented. It is well
known that serial passage increases parasite virulence
[30,31]. This makes it possible to derive parasites, which
differ in virulence but come from the same clonal lineage.
Thus, the effect of chemotherapy on asexual- and trans-
mission-stage densities can be tested on genetically simi-
lar parasites differing in virulence. To mimic the possible
causes of sub-optimal treatment that can occur in the field
(reviewed in the Introduction), parasites were challenged
with sub-optimal doses and sub-optimal duration of drug
treatment when symptoms first appeared.
Parasites
The original Plasmodium chabaudi isolate was obtained
from a thicket rat from the Central African Republic [32].
Genotype CWavir (CW175) was obtained after cloning of
the wild isolate and 4 passages in mice. CWvir (CW202)
was derived from CWavir by 11 serial passages in mice [30]
and became more virulent in the process [33]. Samples of
CWavir and CWvir were passaged a further three times in
C57Bl/6J mice before the experiments described here.
None of the parasite lines involved, nor any of their ances-
tors had been exposed to antimalarial drugs prior to these
experiments.
Experimental set-up
Drug sensitivity to the antimalarial drug pyrimethamine
was tested in vivo using 6–10 week old C57Bl/6J female
mice (Harlan), with access to food (41B maintenance
diet, Harlan) and drinking water supplemented with
0.05% para-amino benzoic acid [34]ad libitum. Mice were
infected with 105 parasites of either CWvir or CWavir by
intraperitoneal injection and given treatment with the
antimalarial drug pyrimethamine from day 5 after infec-
tion, when first symptoms of disease occurred. The exper-
imental setup is shown in Table 1. Pyrimethamine was
administered during four consecutive days in experiment
1 (five mice per group) and experiment 2 (four mice per
group) at doses of 0, 1, 3 and 5 mg/kg or, in experiment
3, on a single day at doses of 0, 4, 8, 12 or 20 mg/kg (four
mice per group). In experiment 1, four mice infected with
CWvir were excluded from analysis, three of these were
severely anaemic and had to be euthanized early in the
experiment (dose 0, n = 1; dose 1, n = 2) and parasites
were not detected at time of treatment in another mouse
(dose 5; Table 1). In experiment 2, all four mice in the
untreated CWvir group had to be euthanized a few days
after the peak of infection on day 11 (n = 1) or 12 (n = 3),
and available data have been used in the analysis unless
indicated otherwise. Pyrimethamine was dissolved in
dimethyl sulphoxide at the required concentration and
injected intraperitoneally with a maximum total volume
of 50 μL. To monitor treatment efficacy, parasite dynamics
and virulence (weight loss, anaemia) were followed until
three weeks post infection, when mice no longer show
disease symptoms. Asexual parasites were counted per
1000 RBCs by examination of Giemsa-stained thin smears
from tail bleeds. Red blood cell density was determined
by flow cytometry (Beckman Coulter) and used to calcu-
late parasite density/mL of blood. Blood samples for RNA
(10 μL) and DNA (5 μL) extraction were stored to quantify
gametocytes by quantitative reverse-transcriptase PCR and
for sequencing to detect pyrimethamine resistance muta-
tions.
Nucleic acid extraction and PCR analysis of gametocytes
Ten μL blood samples were added to 30 μL nucleic acid
purification lysis solution (Applied Biosystems) and 15
μL PBS, gently mixed and stored at -80°C. RNA was
extracted using the ABI Prism 6100® [35] and cDNA was
Table 1: Treatment groups and sample sizes for experiments 1, 2 
and 3
Nr mice exp 1 Nr mice exp 2
Days Dose CWavir CWvir CWavir CWvir
405 5 *4 4 #
4 1 55 * * 44
4 3 55 44
455 5 §4 4
Nr mice exp 3
Days Dose CWavir CWvir
104 4
144 4
184 4
11 2 4 4
12 0 4 4
Days: duration of pyrimethamine treatment in days, starting from day 
5 after infection. Dose: mg/kg/day. Nr mice: sample sizes for each 
group, with sample sizes for each experiment. * Each symbol indicates 
a mouse excluded from analysis, euthanized early in the experiment 
because of severe anaemia. § 1 mouse excluded, no parasites detected 
at time of treatment. # 4 mice euthanized on d11 and d12 after 
infection, data have been used where possible.Malaria Journal 2008, 7:257 http://www.malariajournal.com/content/7/1/257
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obtained by reverse transcriptase PCR (high capacity
cDNA archive kit, Applied Biosystems) according to man-
ufacturer's protocols. Gametocytes were counted using
quantitative real-time PCR with primers based on the
gametocyte-specifically expressed gene PC302249.00.0
[36].
During qPCR analysis for gametocyte quantification,
three different dilution series of positive control samples,
initiated from different mice with P. chabaudi gameto-
cytes, were tested in concentrations ranging from 7 to
7*106 gametocytes/mL. The average threshold cycle (Ct)
values ± 1 standard deviation are shown in Figure 2.
Gametocyte numbers have a high correlation to Ct values
(R2 = 0.99; p < 0.0001). The absolute detection limit for
the assay was determined to be at least 700 gametocytes/
mL of blood. Lower gametocyte densities were detected in
88% (221 gametocytes/mL), 67% (71/mL), 43% (22/mL)
and 12% (7/mL) of the tested control samples. This
decline in probability of detection is most likely related to
the probability of target nucleic acid being present in the
10 μL blood sample.
Classical drug resistance genotyping
Pyrimethamine is an antifolate drug that inhibits the
enzyme dihydrofolate reductase (DHFR) that is essential
in the folic acid pathway, ultimately leading to pyrimidine
synthesis. Pyrimethamine inhibits parasite multiplication
but does not directly kill gametocytes. As with other
malaria parasite species, resistance to pyrimethamine in P.
chabaudi is conferred by point mutations in the dhfr gene,
resulting in conformational changes of the enzyme and
decreased binding capacity of the drug [37,38]. Samples
from the day of infection and day 21 were analysed to
detect resistance mutations in the dhfr gene, using the fol-
lowing protocol. DNA was extracted using InstaGene
Matrix (BioRad) according to the standard protocol for
DNA preparation from whole blood. The extracted DNA,
forward primer pcdhfr-10 5'-GCTATTTCTTTCTA-
CATTTGC-3' and reverse primer pcdhfr-11 5'-TTTAAAAT-
GATGAGCATGCTC-3' were used to amplify the region of
the dhfr gene that contains possible mutations involved in
pyrimethamine resistance. The PCR reaction included
13.75 μL water, 10 μL 5× PCR buffer (Promega), 3 μL 25
mM MgCl2, 1 μL dNTPs 10 mM, 0.25 μL Taq 5 u/μL, 1 μL
of each primer 10 μM and 20 μL DNA sample. The tem-
PCR quantification of P. chabaudi gametocytes Figure 2
PCR quantification of P. chabaudi gametocytes. Average threshold value (Ct) ± standard deviation for P. chabaudi game-
tocyte control samples tested in 25 different 96-well plates for quantitative PCR.
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perature programme used for amplification was 95°C for
60 seconds, then 30 cycles of each 95°C for 60 seconds,
52°C for 60 seconds, 65°C for 60 seconds and ending
with 65°C for 600 seconds and storage at 4°C. PCR prod-
ucts were purified using Qiaquick PCR purification kit
(Qiagen Ltd. UK) according to manufacturer's protocol
and sequenced.
Statistics
The maximum and cumulative measures of parasite and
gametocyte density achieved by each infection during the
21-day experiments were used as response variables in the
analysis. Plasmodium chabaudi has a cell-cycle of approxi-
mately one day for asexual parasites, therefore, cumula-
tive parasite density is a measure of the total number of
parasites present during a defined period of the infection.
Gametocyte density correlates positively with infectivity
to mosquitoes [21,39] and, when summed over the
course of an infection, provides a measure of transmission
potential. Cumulative parasite and gametocyte counts
were log10-transformed to meet assumptions of normality
and homogeneity of variance. Analyses were performed
using general linear models in SPSS version 14.0 (SPSS
Inc., Chicago, USA). Full models for analysis of parasite
data included the main effects of clone (CWavir or CWvir;
virulence classification) and dose, their 2-way interaction,
experiment (1–3) as a random factor, and the covariates
weight and anaemia at the day of infection as well as par-
asite density at the start of treatment. The clone × dose
interaction indicates that CWvir and CWavir were differen-
tially affected by drug dose, the hypothesis under test (Fig-
ure 1). Models were minimized using step-wise deletion.
Results
Virulence of ancestral and derived parasites in the absence 
of drug-treatment
As found previously [33], CWvir was indeed more virulent
in the absence of chemotherapy, generating greater weight
loss and anaemia than CWavir (Figure 3; mean difference ±
s.e. of maximum weight loss: 15 ± 2% of starting body
mass; F1,21 = 68.6, p < 0.001; mean difference ± s.e. 12 ±
2% of starting RBC density; F1,21 = 47.9, p < 0.001).
Asexual parasites
In the absence of drugs, CWvir achieved higher maximum
asexual parasite densities than CWavir (mean difference ±
s.e. 9.9 ± 2.5 × 108, F1,21 = 21.5, p < 0.001). Drug treatment
reduced maximum asexual parasite density and delayed
peak parasite density in a dose-dependent manner (Figure
4). At all doses, cumulative asexual parasite density was
reduced by drug treatment (dose effect, F7,90 = 58.9, p <
0.0001), but remained significantly higher in CWvir than
CWavir infections (Figure 5; clone effect, F1,90 = 153.4, p <
0.0001). The relative reduction in parasites densities
induced by the different doses differed between the CWvir
and CWavir (clone × dose interaction F7,90 = 3.6, p = 0.002),
with the impact disproportionately greater on CWavir.
Thus, sub-optimal chemotherapy enhanced the relative
difference in cumulative parasite densities between the
two clonal lineages (Figure 5).
Gametocytes
In the absence of drug treatment, CWvir infections had
higher peak gametocyte densities (mean difference ± s.e.
34.4 ± 12.8 × 106, F1,19 = 7.3, p = 0.014) as well as higher
total gametocyte production (Figure 6; F1,15 = 30.9, p <
0.001) than CWavir infections.
Total gametocyte numbers were significantly reduced by
treatment (dose effect, F7,82 = 16.0, p < 0.001) and the
higher transmission potential for CWvir is generally main-
tained under conditions of drug treatment (clone effect
F1,82 = 51.7, p < 0.001).
Overall the experiments, the effect of drug treatment on
the two parasite lines was marginally different (clone ×
dose interaction F7,82 = 2.1, p = 0.06). However, breaking
these data down by experiment showed that there was no
general pattern (Figure 6). Gametocyte densities in the
third experiment, which involved one day of treatment
show similar patterns (Figure 6C) to those seen in the
asexual densities (Figure 5), but the disproportionate
reductions in transmission potential of CWavir  at the
higher doses was not statistically significant (clone × dose
F4,17 = 1.62, p = 0.196). Due to loss of data for the
untreated CWvir group in experiment 2 (see Methods), it is
not possible to determine the differences in transmission
potential between the two lines in the absence of treat-
ment (Figure 6B). Among the remaining (treated) groups,
the different doses had similar effects on both CWvir and
CWavir (clone × dose F2,20 = 0.11, p = 0.901). In experiment
1, the clone differences did vary with treatment (clone ×
dose F3,24 = 9.45, p < 0.001), but inspection of Figure 6A
shows that chemotherapy is causing similar proportionate
reductions in gametocyte numbers for both lines except at
an intermediate dose, which was disproportionately effec-
tive against CWvir (or ineffective against CWavir). The cause
for this effect is unknown and it was not observed in the
repeat experiment (Figure 6B).
Dhfr mutations
Mutations known to confer resistance to the drug
pyrimethamine in P. chabaudi [37,38] in parasites of
either clonal lineages were not observed, either at the start
of the infections, or among parasites surviving treatment
and present on day 21 post-infection, the last day of the
experiment.
Discussion
In this study, the drug sensitivity of two parasite lines, one
derived from the other by serial passage [30] were com-
pared. The virulent derived line was significantly less sen-Malaria Journal 2008, 7:257 http://www.malariajournal.com/content/7/1/257
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sitive to sub-optimal pyrimethamine treatment (Figures 4
and 5). This decreased sensitivity to pyrimethamine was
not associated with the presence at detectable levels of
mutations known to confer classical drug resistance
[37,40]. Because of this, and because these parasite lines
had never previously been exposed to pyrimethamine and
because possible between-host variation in immune
response and bioavailability have been controlled for by
using inbred hosts, these data provide evidence for 'non-
classical' drug resistance in malaria parasites.
These data raise several potentially important questions.
First, is the differential susceptibility to drugs due to para-
site factors associated with virulence? Higher parasite den-
sities at the time of treatment could be associated with
both virulence and the ability to recover from sub-optimal
chemotherapy [17-20]. However, parasite density at time
of treatment was included as a covariate in all analyses
and it is therefore unlikely that higher parasite densities
per se are responsible for the patterns reported. Clearly,
with a comparison of two lines, it is not possible to
attribute the cause of the differential susceptibility to any
specific difference between CWvir and CWavir. Nonethe-
less, these two lines have almost identical genotypes and
the most obvious difference between them is that the
derived line is more virulent. Establishing whether viru-
lence is responsible for the 'non-classical drug resistance'
observed requires more data.
Second, could sub-optimal chemotherapy impose selec-
tion in favour of more virulent parasites? Subject to the
normal cautions about generalizing from animal models
(reviewed in this context by Wargo et al [41]), these data
suggest it could. The avirulent parasites were dispropor-
tionately suppressed (Figure 5), implying that within-host
selection imposed by drug pressure will favour virulent
Infections with CWvir resulted in greater weight loss and red blood cell loss than CWavir Figure 3
Infections with CWvir resulted in greater weight loss and red blood cell loss than CWavir. Virulence measures for P. 
chabaudi CWavir and CWvir without drug treatment. Mean ± s.e. values over 13 (CWavir) and 12 (CWvir) infections combined 
for experiments 1, 2 and 3 are shown. Statistical difference between lines after adjustment for between-experiment differences 
(experiment) are at 0.001 level (**).
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parasites. To determine directly whether this within-host
selective advantage translates into a between-host (trans-
mission) advantage requires assays involving mosquitoes,
a high priority for future work. We found no consistent
evidence that the transmission stage densities of the viru-
lent parasite line were less affected by treatment than
those of the avirulent line, but the relationship between
gametocyte density and mosquito infection can be influ-
enced by several non-mutually exclusive factors (e.g. [42-
45]), and malaria parasites can compensate for mild levels
of drug-induced mortality by the production of more
transmission stages [46-48]. We expect that if co-infection
of both the virulent and avirulent line were drug treated,
the within-host selective advantage of the virulent line
would translate into greater relative transmission.
Chemotherapy could also drive virulence evolution by a
completely different evolutionary mechanism. Virulence
theory assumes that whilst virulence and transmission are
positively correlated in the absence of host death, exces-
sively virulent parasites risk truncating their infectious
period by prematurely killing their host. Under this sce-
Effects of pyrimethamine treatment on parasite dynamics of virulent and avirulent P. chabaudi Figure 4
Effects of pyrimethamine treatment on parasite dynamics of virulent and avirulent P. chabaudi. Number of asex-
ual parasites/ml of blood over time ± s.e. for increasing pyrimethamine doses. PYR0 = no drug, PYR1, 3, 4, 5, 8, 12 and 20 indi-
cate daily doses of pyrimethamine in mg/kg. 4A. 4-day pyrimethamine treatment, combined for experiments 1 and 2 with 9 
mice in all treatment groups, except CWvir dose 5 (n = 8). Death of mice during the experiment is indicated by the table below 
the CWvir graph. 4B. Experiment 3, 1-day treatment with 4 mice in each treatment group.
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nario, it is host death that restrains the evolution of ever
more virulent parasites. A logical consequence of this view
is that interventions which keep hosts alive reduce this
restraining force, while still allowing parasites to benefit
from the transmission rewards of increasing their viru-
lence. Thus life-protecting interventions have the poten-
tial to allow more virulent strains to circulate in malaria
populations [49]. This hypothesis is supported by obser-
vations that virulence increases with serial passage
[30,31], and theoretical analysis of the evolutionary con-
sequences of vaccination [50-52] or chemotherapy
[53,54] predict virulence to increase. If sub-optimal drug
treatment reduces the costs of virulence (hypothesized) as
well as conferring a survival advantage on virulent para-
sites (as the data reported here indicate), chemotherapy
could be a potent force for the evolution of more virulent
parasites.
These ideas and the data reported here, raise several ques-
tions that could be explored theoretically. First, will there
be positive feedback, whereby the frequency of sub-opti-
mally treated infections will rise as the virulent parasites
favoured by sub-optimal therapy become more common?
Can this process be halted by increasing drug doses? Sec-
ond, combination therapy is now recommended by the
WHO because it reduces the probability that classical
drug-resistance mutations can emerge in the first place. By
preventing classical resistance from arising, is combina-
tion therapy making virulence evolution more likely?
There will almost certainly already be standing genetic
variation in virulence in nature on which selection can act.
Third, will classical resistance, when it does arise, be more
likely to appear in more virulent parasites? Fourth, could
virulence-related susceptibility to drugs act as a form of
cross-resistance which continue to protect parasites when
policy switches to new drugs after failure of current com-
binations? The preliminary data reported here, are obvi-
ously far from the final word, but given the potential
importance of the problem, these preliminary data
strongly argue for further investigation of questions like
these, and of course further empirical investigation of the
phenomenon of virulence-mediated drug sensitivity.
Conclusion
Virulent parasites were disproportionately less susceptible
to sub-optimal drug treatment than were less virulent par-
asites. It is important to determine whether virulence-
dependent drug sensitivity occurs across a variety of drugs,
treatment regimes and parasite species. If it does, selection
imposed by sub-optimal drug treatment could cause the
evolution of more virulent parasites, rendering future
infections more aggressive.
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Effects of pyrimethamine treatment on total asexual parasite density during an infection Figure 5
Effects of pyrimethamine treatment on total asexual parasite density during an infection. Total asexual parasites/
mL blood summed for days 6–21 after treatment ± standard error. PYR0 = no drug, PYR1, 3, 4, 5, 8, 12 and 20 indicate daily 
doses of pyrimethamine in mg/kg. 5A: experiments 1 and 2 combined. 5B: Experiment 3.
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Effects of pyrimethamine treatment on total gametocyte density during an infection Figure 6
Effects of pyrimethamine treatment on total gametocyte density during an infection. Total gametocytes/mL blood 
± s.e. summed over the duration of infection. PYR0 = no drug, PYR1, 3, 4, 5, 8, 12 and 20 indicate daily doses of pyrimethamine 
in mg/kg. Figure 6A and B. 4-day treatment experiments 1 and 2, summed for days 6–21. Data for the untreated CWvir group is 
missing as a result of host death on days 11 and 12. Figure 6C. Experiment 3, 1-day treatment, summed for days 6–19.
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